Veterinary Medicines

OFTALMOCAN FATRO COLIRIO EN SOLUCION

Authorised
  • Chloramphenicol
  • Prednisolone sodium phosphate
  • Lidocaine
Download as PDF

Product identification

Medicine name:
OFTALMOCAN FATRO COLIRIO EN SOLUCION
Active substance:
  • Chloramphenicol
  • Prednisolone sodium phosphate
  • Lidocaine
Target species:
  • Dog
  • Cat
Route of administration:
  • Ocular use

Product details

Active substance and strength:
  • Chloramphenicol
    3.00
    milligram(s)
    /
    1.00
    millilitre(s)
  • Prednisolone sodium phosphate
    3.00
    milligram(s)
    /
    1.00
    millilitre(s)
  • Lidocaine
    5.00
    milligram(s)
    /
    1.00
    millilitre(s)
Pharmaceutical form:
  • Eye drops, solution
Withdrawal period by route of administration:
  • Ocular use
    • Dog
    • Cat
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QS03CA02
Legal status of supply:
  • Veterinary medicinal product subject to veterinary prescription
Authorisation status:
  • Valid
Authorised in:
  • Spain
Package description:

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Full application - Known active substance (Article 12(3) of Directive No 2001/82/EC)
Marketing authorisation holder:
  • Fatro Iberica S.L.
Marketing authorisation date:
Manufacturing sites for batch release:
  • Labiana Pharmaceuticals S.L.U
Responsible authority:
  • Spanish Agency Of Medicines And Medical Devices
Authorisation number:
  • 2402 ESP
Date of authorisation status change:

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.
Spanish (PDF)
Published on: 9/11/2022
Download

Labelling

This document does not exist in this language (English). You can find it in another language below.
Spanish (PDF)
Published on: 9/11/2022
Download

Package Leaflet

This document does not exist in this language (English). You can find it in another language below.
Spanish (PDF)
Published on: 9/11/2022
Download
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."